New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
November 29, 2012
07:58 EDTAMRNAmarin says continues to see Vascepa launch early in 1Q13
Amarin previously guided that it would make a decision to hire prospective sales representatives as part of its continued Vascepa commercialization preparations before the end of November. Amarin now expects to make this decision in the first half of December and continues to anticipate the launch of Vascepa early in 1Q13.
News For AMRN From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
November 19, 2014
15:00 EDTAMRNStonepine Capital reports 5.2% passive stake in Amarin
November 17, 2014
09:06 EDTAMRNAmarin reports new data from MARINE, ANCHOR phase 3 studies
Amarin announced the presentation of new data and related analyses from the MARINE and ANCHOR phase 3 studies. The data show that use of Vascepa capsules significantly reduced remnant-like particle cholesterol, or RLP-C, levels -- a cardiovascular risk factor -- including significant placebo-adjusted reductions in RLP-C in studied patient populations with triglyceride, or TG, levels greater than or equal to 200 mg/dL and greater than or equal to 500 mg/dL, including patients that received statin therapy. The data were presented today by Dr. Christie M. Ballantyne as part of a moderated poster session at the American Heart Association Scientific Sessions in Chicago. Remnant-like particle cholesterol is an important emerging risk factor for cardiovascular disease and represents the cholesterol content of a subset of triglyceride-rich lipoproteins, or TRL, called remnants. In the fasting state this subset of TRLs is comprised of very low-density lipoproteins, or VLDL, and intermediate-density lipoproteins, or IDL, and in the non-fasting state includes these two types of lipoproteins together with chylomicron remnants.Elevated plasma TG levels are a marker of elevated remnant cholesterol and are associated with increased risk for cardiovascular disease.
November 6, 2014
16:02 EDTAMRNAmarin reports Q3 EPS (17c), consensus (13c)
Reports Q3 revenue $14.15M, consensus $15.07M.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use